A Review of Virus-Like Particle-Based SARS-CoV-2 Vaccines in Clinical Trial Phases.

ABSTRACT: The Coronavirus disease 2019 (COVID-19) pandemic has affected more than 269 million worldwide, with more than five million deaths as of early December 2021. The main concerns in this pandemic include the asymptomatic nature of COVID-19, leading to the infection of many healthy people, the infectious nature of the pathogen, and its high spreading rate. The disease features have highlighted the importance of controlling this pandemic via vaccines. There has been a worldwide race to produce better, more protective, and efficacious vaccines. Simultaneously, different new variants of the virus are emerging. Therefore, there is a concern about the efficacy of the vaccines against new variants. The platform used for COVID-19 vaccine development needs to be flexible enough to enable the manufactur

SUBMITTER: Sharifzadeh M 

PROVIDER: S-EPMC9293385 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature